NEW YORK (GenomeWeb) – By systematically introducing mutations into the BRCA1 gene, researchers have sought to better classify which variants are likely to be pathogenic or benign.
BRCA1 is one of the best-studied genes, but the impact of its numerous variants on breast and ovarian cancer risk remains unclear. Such variants of uncertain significance (VUS) limit the clinical utility of a patient's data, said the authors of the new study.